Epiendo pharmaceuticals events
WebFeb 24, 2024 · EpiEndo’s lead drug candidate, EP395, aims to be the first on-market oral, disease modifying, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for COPD. For more information ... WebAug 18, 2024 · EpiEndo’s development rationale is based on a newly acknowledged therapeutic paradigm, that loss of integrity of epithelial barriers plays a critical role in …
Epiendo pharmaceuticals events
Did you know?
WebMar 24, 2024 · EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on enhancement of epithelial barrier … WebFeb 24, 2024 · EpiEndo Pharmaceuticals is a privately held biopharmaceutical company currently developing a next-generation therapeutic platform for the treatment of inflammatory disorders through …
WebAug 31, 2024 · EpiEndo Pharmaceuticals: Maria Bech, CEO Email: [email protected] Tel: +354 454 0090 Instinctif Partners (media relations): Rozi Morris / Katie Duffell Email: [email protected] Tel: +44 ... WebNov 15, 2024 · Labiotech.eu covers the global biotech industry, read by 150,000+ monthly visitors. Hope you'll enjoy our Biotech News!
WebOct 23, 2024 · EpiEndo is developing a candidate drug with a novel mode of action that, if successfully brought to the patients, could change the treatment paradigm for COPD,” said Eugen Steiner, member of the award jury. “EpiEndo won the top scores from all judges in the criteria of innovation and impact, giving it the lead over competitors. WebApr 13, 2024 · EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on the enhancement of epithelial barrier integrity as a causal pathophysiological factor underlying the etiology of …
WebApr 15, 2024 · REYKJAVIK, ICELAND – 15 April 2024 – EpiEndo Pharmaceuticals (www.epiendo.com), a clinical-stage biopharmaceutical company developing novel non-antibiotic macrolide therapeutics for the …
WebMar 24, 2024 · REYKJAVIK, Iceland--(BUSINESS WIRE)-- EpiEndo Pharmaceuticals is pleased to announce the appointment of Stefan Petursson as Chief Financial Officer (CFO), starting 1 April 2024.EpiEndo Pharmaceuticals is a privately held biopharmaceutical company developing a therapeutic pipeline for the treatment of inflammatory disorders … reloj marca crrju precioWebDec 19, 2024 · EpiEndo Pharmaceuticals Overview Update this profile Founded 2014 Status Private Employees 17 Latest Deal Type Series A Latest Deal Amount $23.6M Investors 7 General Information Description Developer of drugs and proprietary compounds intended to offer new treatments for chronic airway diseases. reloj marca gffWebOct 25, 2024 · EpiEndo Pharmaceuticals wins the Swedish American Life Sciences Summit (SALSS) Rising Star Award 2024. Maria Bech, CEO and Dr Fridrik Gardarsson, … reloj marca glam rockWebAug 18, 2024 · EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on enhancement of epithelial barrier integrity as a critical pathophysiological factor underlying the etiology of … edina balogh linkedinWebPhone Number 00 354 454 0090. EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on the enhancement of … edim canoskiWebMar 24, 2024 · EpiEndo Pharmaceuticals: Maria Bech, CEO E-mail: [email protected] Tel: +354 454 0090 Instinctif Partners (media relations): Rozi Morris / Katie Duffell Tel: +44 20 7457 2024 Site Navigation edimdoma.ru рецептыWebApr 6, 2024 · EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on the enhancement of epithelial barrier integrity as a causal pathophysiological factor underlying the etiology of … reloj marcador bac honduras svenka.mobi